Date: 2017-09-11
Type of information: Series A financing round
Company: IGEM Therapeutics (UK)
Investors: Epidarex Capital (UK)
Amount: £2 million
Funding type: series A financing round
Planned used:
- The funding will enable IGEM to continue to invest in pipeline development as it builds its portfolio of IgE antibody candidates, including those that target folate receptor alpha, HER2, EGFR and PD-L1, and will support the further development of IgE antibody platform technology based on protein and glyco-engineering.
- IGEM will benefit from the expertise of scientific founder Dr. Sophia Karagiannis of King’s College London who is recognised as a world leader in the field. The epsilon constant region of IgE has evolved to fight complex, multicellular parasitic organisms resident in tissue by recruiting powerful immune effector cells such as macrophages, basophils and monocytes. IGEM believes that potent immune responses arising from IgE are suited to the destruction of solid tumours which also reside in tissue. Dr Karagiannis’s team has demonstrated superior efficacy for IgE versus cognate immunoglobulin G (IgG) antibodies in a range of pre-clinical cancer models.
Others:
- • On August 11, 2017, IGEM Therapeutics, an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announced the closing of a £2 million Series A investment from Epidarex Capital, a specialist early stage life science venture capital firm. Igem is now seeking further investment to complete the round.
- In addition, IGEM has announced the appointment of Dr. Tim Wilson as Chief Executive Officer. Tim Wilson joins IGEM as Chief Executive Officer with 28 years of experience in the life sciences sector, ranging from venture capital and start-ups to investment banking and equity research. He has worked with hundreds of private and public life science companies in the US and Europe at all stages of development, from start-ups to industry leaders. He holds a PhD in molecular biology from Cambridge University and a BSc in biochemistry from Imperial College, London.
Therapeutic area: Cancer - Oncology
Is general: Yes
